<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183908</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00083845</org_study_id>
    <nct_id>NCT03183908</nct_id>
  </id_info>
  <brief_title>FLUAD® vs. Fluzone® High-Dose Study</brief_title>
  <official_title>Safety and Immunogenicity of Adjuvanted Versus High-Dose Inactivated Influenza Vaccines in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the study is to compare safety and immunogenicity of inactivated influenza&#xD;
      vaccine (IIV), adjuvanted (FLUAD®) versus High-Dose inactivated influenza (Fluzone®&#xD;
      High-Dose) vaccine in persons ≥65 years (20% aged ≥80 years). A prospective, randomized,&#xD;
      blinded clinical trial that will be conducted during the 2017/2018 and 2018/2019 influenza&#xD;
      seasons. During each season, approximately 220 older adults will be enrolled at Duke&#xD;
      University Medical Center and 140 older adults at Boston University Medical Center. Eligible&#xD;
      subjects will be randomized to receive either adjuvanted influenza vaccine or High-Dose&#xD;
      influenza vaccine. All subjects will receive vaccine and provide a blood draw at Visit 1, and&#xD;
      then return for a second blood draw without vaccination about 4 weeks later to assess for&#xD;
      influenza antibody titers. A subset of 100 subjects at Duke will provide a third blood draw 6&#xD;
      months post-vaccination to assess for waning of influenza antibody titers. Subjects will&#xD;
      record the occurrence of local and systemic reactions (including fever, pain, tenderness,&#xD;
      swelling, redness, general systemic systems), unsolicited adverse events, medical care&#xD;
      utilization, and changes in medications over 8 days following vaccination. In addition,&#xD;
      serious adverse events and events of clinical interest will be assessed through 42 days&#xD;
      post-vaccination. Health-related quality of life will be assessed pre-vaccination (Day 1) and&#xD;
      on Days 3 and 9 post-vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Full Analysis Population 1: Defined as all subjects who are randomized, vaccinated, and&#xD;
      provide at least one day of complete data on the symptom diary.&#xD;
&#xD;
      Full Analysis Population 2: Defined as all subjects who are randomized and vaccinated.&#xD;
&#xD;
      Immunogenicity Population: Defined as subjects who received vaccine, provided baseline and&#xD;
      Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame&#xD;
      with no protocol violations affecting immunogenicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Actual">February 14, 2019</completion_date>
  <primary_completion_date type="Actual">February 14, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subject, study coordinators, and investigators will be blinded to the type of flu vaccine administered. Only the vaccinator will be unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Injection-Site Pain in Arm That Was Vaccinated, Population 1</measure>
    <time_frame>Days 1 through 8 post-vaccination</time_frame>
    <description>Comparison of the proportion of subjects reporting moderate/severe injection site pain within the first week post-vaccination in both treatment groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events of Clinical Interest, Population 2</measure>
    <time_frame>42 days post-vaccination and compared between the two groups.</time_frame>
    <description>The frequency and descriptions of adverse events of clinical interest observed in the two treatment groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Serious Adverse Events in Both Treatment Groups, Population 2</measure>
    <time_frame>42 days post-vaccination and compared between the two groups.</time_frame>
    <description>The frequency and descriptions of serious adverse events observed in the two treatment groups.&#xD;
No analytical analysis was completed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With H3N2 HAI Seroconversion</measure>
    <time_frame>29 days post-vaccination</time_frame>
    <description>H3N2 hemagglutination inhibition assay (HAI) seroconversion: The proportion of subjects achieving H3N2 seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer is &gt; 1:10) in the respective season's vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Reactions in Arm That Was Vaccinated - Full Study, Population 1</measure>
    <time_frame>Days 1 through 8 post-vaccination</time_frame>
    <description>Comparison of local reactions within the first week post-vaccination in both treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Reactions in Arm That Was Vaccinated - Ages 65 - 79, Population 1</measure>
    <time_frame>Days 1 through 8 post-vaccination</time_frame>
    <description>Comparison of local reactions within the first week post-vaccination in both treatment groups by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Reactions in Arm That Was Vaccinated - Ages 80 +, Population 1</measure>
    <time_frame>Days 1 through 8 post-vaccination</time_frame>
    <description>Comparison of local reactions within the first week post-vaccination in both treatment groups by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Systemic Reactions - Full Study Population, Population 1</measure>
    <time_frame>Days 1 through 8 post-vaccination</time_frame>
    <description>Comparison of systemic reactions within the first week post-vaccination in both treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With System Reactions - Ages 65 - 79, Population 1</measure>
    <time_frame>Days 1 through 8 post-vaccination</time_frame>
    <description>Comparison of systemic reactions within the first week post-vaccination in both treatment groups by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With System Reactions - Ages 80 +, Population 1</measure>
    <time_frame>Days 1 through 8 post-vaccination</time_frame>
    <description>Comparison of systemic reactions within the first week post-vaccination in both treatment groups by age group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Late Life Function &amp; Disability Instrument - Full Population</measure>
    <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
    <description>Change in scores on the Late Life Function &amp; Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes.&#xD;
The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1).&#xD;
The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Late Life Function &amp; Disability Instrument - Ages 65 - 79</measure>
    <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
    <description>Change in scores on the Late Life Function &amp; Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes.&#xD;
The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1).&#xD;
The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Late Life Function &amp; Disability Instrument - Ages 80 +</measure>
    <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
    <description>Change in scores on the Late Life Function &amp; Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes.&#xD;
The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1).&#xD;
The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EQ-5D-5L -Full Population</measure>
    <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
    <description>Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups (Year 1 only).&#xD;
Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EQ-5D-5L - Ages 65 - 79</measure>
    <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
    <description>Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only).&#xD;
Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EQ-5D-5L - Ages 80 +</measure>
    <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
    <description>Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only)&#xD;
Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EQ VAS -Full Population</measure>
    <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
    <description>Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups (Year 1 only).&#xD;
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EQ VAS - Ages 65 - 79</measure>
    <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
    <description>Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only).&#xD;
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EQ VAS - Ages 80 +</measure>
    <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
    <description>Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only).&#xD;
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion - 65 and Older</measure>
    <time_frame>Day 29 (28 days post-vaccination)</time_frame>
    <description>The proportion of subjects achieving seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection - 65 and Older</measure>
    <time_frame>Day 29 (28 days post-vaccination)</time_frame>
    <description>Proportion of subjects with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean HAI Titer - 65 and Older</measure>
    <time_frame>Day 29 (28 days post-vaccination)</time_frame>
    <description>The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion - Ages 65-79</measure>
    <time_frame>Day 29 (28 days post-vaccination)</time_frame>
    <description>The proportion of subjects aged 65-79 achieving seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion - Ages 80 and Older</measure>
    <time_frame>Day 29 (28 days post-vaccination)</time_frame>
    <description>The proportion of subjects ages 80 and older achieving seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection - Ages 65-79</measure>
    <time_frame>Day 29 (28 days post-vaccination)</time_frame>
    <description>Proportion of subjects ages 65-79 with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection - Ages 80 and Older</measure>
    <time_frame>Day 29 (28 days post-vaccination)</time_frame>
    <description>Proportion of subjects ages 80 and older with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean HAI Titer - Ages 65-79</measure>
    <time_frame>Day 29 (28 days post-vaccination)</time_frame>
    <description>The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine for ages 65-79</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean HAI Titer - Ages 80 and Older</measure>
    <time_frame>Day 29 (28 days post-vaccination)</time_frame>
    <description>The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine for ages 80 and older</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">757</enrollment>
  <condition>Pain</condition>
  <condition>Quality of Life</condition>
  <condition>Injection Site Reaction</condition>
  <condition>Side Effect of Drug</condition>
  <condition>Adverse Drug Event</condition>
  <arm_group>
    <arm_group_label>Adjuvanted influenza vaccine (FLUAD®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the study arm, subjects will receive a single dose of FLUAD® adjuvanted influenza vaccine during Visit 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose influenza vaccine (Fluzone® HD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the study arm, subjects will receive a single dose of Fluzone® High-Dose influenza vaccine during Visit 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FLUAD®</intervention_name>
    <description>Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
    <arm_group_label>Adjuvanted influenza vaccine (FLUAD®)</arm_group_label>
    <other_name>Adjuvanted influenza vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® High-Dose</intervention_name>
    <description>Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
    <arm_group_label>High-dose influenza vaccine (Fluzone® HD)</arm_group_label>
    <other_name>High-dose influenza vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Persons aged ≥65 years, living in the community&#xD;
&#xD;
          2. Intention of receiving IIV vaccine based on ACIP-CDC guidelines&#xD;
&#xD;
          3. Willing to provide written informed consent prior to initiation of any study&#xD;
             procedures&#xD;
&#xD;
          4. Able to speak English&#xD;
&#xD;
          5. Able and willing to complete baseline assessments and questionnaires, and to allow&#xD;
             information to be collected from their electronic medical record&#xD;
&#xD;
          6. Able and willing to complete post-vaccine assessments and questionnaires independently&#xD;
             or with assistance&#xD;
&#xD;
          7. Able and willing to have blood drawn for the study&#xD;
&#xD;
          8. Able and willing to return in about one month for a follow-up visit including&#xD;
             completing questionnaires and having another blood test&#xD;
&#xD;
          9. Access to and ability to use a phone, independently or with assistance&#xD;
&#xD;
         10. Adequate vision and motor skills to complete the diary form independently or with&#xD;
             assistance.&#xD;
&#xD;
         11. Not living in a skilled nursing facility/nursing home/long term acute care facility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. IIV receipt during the current influenza season prior to study enrollment&#xD;
&#xD;
          2. Enrolled in this study during the 2017-18 (Year 1) influenza season&#xD;
&#xD;
             Note: Year 1 study participants will only be enrolled in Year 2 if they are&#xD;
             participating in the sub-study on repeat vaccination&#xD;
&#xD;
          3. Has immunosuppression as a result of an underlying illness or treatment, or use of&#xD;
             anti-cancer chemotherapy or radiation therapy within the preceding 12 months.&#xD;
&#xD;
          4. Has an active neoplastic disease (excluding non-melanoma skin cancer or prostate&#xD;
             cancer that is stable in the absence of therapy) or a history of any hematologic&#xD;
             malignancy*&#xD;
&#xD;
             *Participants with a history of malignancy may be included if, after previous&#xD;
             treatment by surgical excision, chemotherapy or radiation therapy, the participant has&#xD;
             been observed for a period that in the investigator's estimation provides a reasonable&#xD;
             assurance of sustained cure (not less than 12 months)&#xD;
&#xD;
          5. Thrombocytopenia, bleeding disorder, or anticoagulant use contraindicating&#xD;
             intramuscular injection&#xD;
&#xD;
          6. History of febrile illness (&gt; 100.0°F or 37.8°C) within the past 24 hours prior to IIV&#xD;
             administration (temporary deferral)&#xD;
&#xD;
          7. Contraindication to IIV receipt including history of severe allergic reaction after a&#xD;
             previous dose of any influenza vaccine; or to a vaccine component*, including egg&#xD;
             protein; or a latex allergy&#xD;
&#xD;
             *Formaldehyde, Octylphenol ethoxylate, neomycin, kanamycin, barium,&#xD;
             cetyltrimethlyammonium bromide (CTAB)&#xD;
&#xD;
          8. Any history of Guillain-Barré syndrome&#xD;
&#xD;
          9. Mild to severe dementia as determined by the Mini-Cog tool and the Rowland Universal&#xD;
             Dementia Assessment Scale (RUDAS)&#xD;
&#xD;
         10. Substance use that could interfere with study compliance&#xD;
&#xD;
         11. Receipt of any inactivated licensed vaccine within 2 weeks, or live attenuated&#xD;
             licensed vaccine within 4 weeks prior to enrollment in this study, or planning receipt&#xD;
             of any vaccines during the 42-days post-vaccination period (including pneumococcal&#xD;
             vaccines)&#xD;
&#xD;
         12. Anyone who is already enrolled or plans to enroll in another clinical trial with an&#xD;
             investigational product within 28 days of vaccine receipt. Co-enrollment in&#xD;
             observational or behavioral intervention studies are allowed at any time while&#xD;
             enrollment in a clinical trial involving an investigational product (other than&#xD;
             vaccine) may occur after 30 days following vaccine receipt.&#xD;
&#xD;
         13. Hearing loss determined by the investigators to prevent successful communication over&#xD;
             the phone&#xD;
&#xD;
         14. Any condition which, in the opinion of the investigators, may pose a health risk to&#xD;
             the subject or interfere with the evaluation of the study objectives.&#xD;
&#xD;
         15. Anyone who is a relative or subordinate of any research study personnel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Schmader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theresa Harrington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Barnett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centers for Disease Control and Prevention</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <results_first_submitted>February 13, 2020</results_first_submitted>
  <results_first_submitted_qc>March 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2021</results_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza vaccine</keyword>
  <keyword>fever following vaccination</keyword>
  <keyword>pain following vaccination</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Injection Site Reaction</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03183908/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
          <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
        </group>
        <group group_id="P2">
          <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
          <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="378"/>
                <participants group_id="P2" count="379"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="378"/>
                <participants group_id="P2" count="377"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missing Symptom Diary Data</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The primary analysis population will be the Full Analysis Population 2; defined as all subjects who are randomized and vaccinated.</population>
      <group_list>
        <group group_id="B1">
          <title>Adjuvanted Influenza Vaccine (FLUAD)</title>
          <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
        </group>
        <group group_id="B2">
          <title>High-dose Influenza Vaccine (Fluzone HD)</title>
          <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="378"/>
            <count group_id="B2" value="379"/>
            <count group_id="B3" value="757"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age Group</title>
              <category_list>
                <category>
                  <title>65-79 Years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="296"/>
                    <measurement group_id="B3" value="594"/>
                  </measurement_list>
                </category>
                <category>
                  <title>80 or More</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="697"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Black only</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White Only</title>
                  <measurement_list>
                    <measurement group_id="B1" value="286"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                    <measurement group_id="B2" value="379"/>
                    <measurement group_id="B3" value="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection-Site Pain in Arm That Was Vaccinated, Population 1</title>
        <description>Comparison of the proportion of subjects reporting moderate/severe injection site pain within the first week post-vaccination in both treatment groups.</description>
        <time_frame>Days 1 through 8 post-vaccination</time_frame>
        <population>Full Analysis Population 1</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection-Site Pain in Arm That Was Vaccinated, Population 1</title>
          <description>Comparison of the proportion of subjects reporting moderate/severe injection site pain within the first week post-vaccination in both treatment groups.</description>
          <population>Full Analysis Population 1</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="282"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is allV3 is inferior (i.e., allV3 will have higher rates of moderate/severe injection site pain) to IIV3-HD in regards to the proportion of subjects having moderate or severe injection site pain in the first week post vaccination.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The one-sided non-inferiority test with the alpha level set at 0.025 and non-inferiority margin of 5%, stratified by site.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events of Clinical Interest, Population 2</title>
        <description>The frequency and descriptions of adverse events of clinical interest observed in the two treatment groups.</description>
        <time_frame>42 days post-vaccination and compared between the two groups.</time_frame>
        <population>Full Analysis Population 2</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events of Clinical Interest, Population 2</title>
          <description>The frequency and descriptions of adverse events of clinical interest observed in the two treatment groups.</description>
          <population>Full Analysis Population 2</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Serious Adverse Events in Both Treatment Groups, Population 2</title>
        <description>The frequency and descriptions of serious adverse events observed in the two treatment groups.&#xD;
No analytical analysis was completed.</description>
        <time_frame>42 days post-vaccination and compared between the two groups.</time_frame>
        <population>Full Analysis Population 2</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Serious Adverse Events in Both Treatment Groups, Population 2</title>
          <description>The frequency and descriptions of serious adverse events observed in the two treatment groups.&#xD;
No analytical analysis was completed.</description>
          <population>Full Analysis Population 2</population>
          <units>SAE Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic squamous cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-operative ileus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stress induced cardiomyopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Near syncope due to orthostasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary emboli</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small bowel obstruction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs related to study product</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs not related to study product</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The comparison of the number of participants with reported SAEs regardless of relationship to study product were made using 95% confidence intervals. Results were reported using exact binomial confidence intervals.</non_inferiority_desc>
            <param_type>Comparison of Frequencies</param_type>
            <param_value>2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>4.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The comparison of the number of participants with reported SAEs regardless of relationship to study product were made using 95% confidence intervals. Results were reported using exact binomial confidence intervals.</non_inferiority_desc>
            <param_type>Comparison of Frequencies</param_type>
            <param_value>.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With H3N2 HAI Seroconversion</title>
        <description>H3N2 hemagglutination inhibition assay (HAI) seroconversion: The proportion of subjects achieving H3N2 seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer is &gt; 1:10) in the respective season's vaccine</description>
        <time_frame>29 days post-vaccination</time_frame>
        <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With H3N2 HAI Seroconversion</title>
          <description>H3N2 hemagglutination inhibition assay (HAI) seroconversion: The proportion of subjects achieving H3N2 seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer is &gt; 1:10) in the respective season's vaccine</description>
          <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This objective will be assessed using a one-sided noninferiority test with the alpha level set at 0.025 and noninferiority margin of 10%. The null hypothesis is the allV3 H3N2 seroconversion rate is inferior to IIV3-HD seroconversion rate.</non_inferiority_desc>
            <p_value>0.1245</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Proportions</param_type>
            <param_value>-.0579</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-.1291</ci_lower_limit>
            <estimate_desc>The directional comparison was the lower bound of the confidence interval using a 10% non-inferiority margin.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Reactions in Arm That Was Vaccinated - Full Study, Population 1</title>
        <description>Comparison of local reactions within the first week post-vaccination in both treatment groups.</description>
        <time_frame>Days 1 through 8 post-vaccination</time_frame>
        <population>Full Analysis Population 1</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Reactions in Arm That Was Vaccinated - Full Study, Population 1</title>
          <description>Comparison of local reactions within the first week post-vaccination in both treatment groups.</description>
          <population>Full Analysis Population 1</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="348"/>
                    <measurement group_id="O2" value="341"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shoulder Pain</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="317"/>
                    <measurement group_id="O2" value="326"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="335"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Redness</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Shoulder Pain</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.5</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Swelling</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tenderness</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>1.6</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Reactions in Arm That Was Vaccinated - Ages 65 - 79, Population 1</title>
        <description>Comparison of local reactions within the first week post-vaccination in both treatment groups by age group.</description>
        <time_frame>Days 1 through 8 post-vaccination</time_frame>
        <population>Participants 65-79 years of age in Full Analysis Population 1</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD® adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD®: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone® High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone® High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Reactions in Arm That Was Vaccinated - Ages 65 - 79, Population 1</title>
          <description>Comparison of local reactions within the first week post-vaccination in both treatment groups by age group.</description>
          <population>Participants 65-79 years of age in Full Analysis Population 1</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shoulder Pain</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pain</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="210"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Redness</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Shoulder Pain</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Swelling</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tenderness</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection Site Pain</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Reactions in Arm That Was Vaccinated - Ages 80 +, Population 1</title>
        <description>Comparison of local reactions within the first week post-vaccination in both treatment groups by age group.</description>
        <time_frame>Days 1 through 8 post-vaccination</time_frame>
        <population>Participants 80+ years of age in Full Analysis Population 1</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Reactions in Arm That Was Vaccinated - Ages 80 +, Population 1</title>
          <description>Comparison of local reactions within the first week post-vaccination in both treatment groups by age group.</description>
          <population>Participants 80+ years of age in Full Analysis Population 1</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shoulder Pain</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pain</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Redness</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Shoulder Pain</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Swelling</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.6</ci_lower_limit>
            <ci_upper_limit>6.1</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tenderness</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection Site Pain</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Systemic Reactions - Full Study Population, Population 1</title>
        <description>Comparison of systemic reactions within the first week post-vaccination in both treatment groups.</description>
        <time_frame>Days 1 through 8 post-vaccination</time_frame>
        <population>Full Analysis Population 1:&#xD;
Four missing patient-reported outcome measures for &quot;Fever&quot; outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Systemic Reactions - Full Study Population, Population 1</title>
          <description>Comparison of systemic reactions within the first week post-vaccination in both treatment groups.</description>
          <population>Full Analysis Population 1:&#xD;
Four missing patient-reported outcome measures for &quot;Fever&quot; outcome.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="340"/>
                    <measurement group_id="O2" value="346"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills/Shivering</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="362"/>
                    <measurement group_id="O2" value="363"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                    <measurement group_id="O2" value="359"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                    <measurement group_id="O2" value="337"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="366"/>
                    <measurement group_id="O2" value="358"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="335"/>
                    <measurement group_id="O2" value="338"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="344"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="334"/>
                    <measurement group_id="O2" value="338"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="357"/>
                    <measurement group_id="O2" value="362"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="378"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="374"/>
                    <measurement group_id="O2" value="374"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arthralgia</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>1.8</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chills/Shivering</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diarrhea</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fatigue</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>3.2</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fever</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.5</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Headache</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Malaise</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>1.8</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Myalgia</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.5</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nausea</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vomiting</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.01 level to adjust for multiple comparisons.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With System Reactions - Ages 65 - 79, Population 1</title>
        <description>Comparison of systemic reactions within the first week post-vaccination in both treatment groups by age group.</description>
        <time_frame>Days 1 through 8 post-vaccination</time_frame>
        <population>Participants 65-79 years of age in Full Analysis Population 1: Three missing &quot;Fever&quot; outcome values for the Fluzone HD group.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With System Reactions - Ages 65 - 79, Population 1</title>
          <description>Comparison of systemic reactions within the first week post-vaccination in both treatment groups by age group.</description>
          <population>Participants 65-79 years of age in Full Analysis Population 1: Three missing &quot;Fever&quot; outcome values for the Fluzone HD group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="266"/>
                    <measurement group_id="O2" value="266"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills/Shivering</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="283"/>
                    <measurement group_id="O2" value="282"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="280"/>
                    <measurement group_id="O2" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                    <measurement group_id="O2" value="258"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="278"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="257"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="260"/>
                    <measurement group_id="O2" value="264"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="261"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="280"/>
                    <measurement group_id="O2" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="298"/>
                    <count group_id="O2" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="294"/>
                    <measurement group_id="O2" value="291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arthralgia</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chills/Shivering</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diarrhea</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fatigue</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fever</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Headache</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Malaise</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Myalgia</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nausea</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vomiting</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With System Reactions - Ages 80 +, Population 1</title>
        <description>Comparison of systemic reactions within the first week post-vaccination in both treatment groups by age group.</description>
        <time_frame>Days 1 through 8 post-vaccination</time_frame>
        <population>Participants 80+ years of age in Full Analysis Population 1: One missing &quot;Fever&quot; outcome value in the Fluzone HD group.&#xD;
No statistical analysis completed on following Outcomes: Chills/Shivering, Headache, Nausea, Vomiting because none reported in this age group.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With System Reactions - Ages 80 +, Population 1</title>
          <description>Comparison of systemic reactions within the first week post-vaccination in both treatment groups by age group.</description>
          <population>Participants 80+ years of age in Full Analysis Population 1: One missing &quot;Fever&quot; outcome value in the Fluzone HD group.&#xD;
No statistical analysis completed on following Outcomes: Chills/Shivering, Headache, Nausea, Vomiting because none reported in this age group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills/Shivering</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mod/Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arthralgia</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diarrhea</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fatigue</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fever</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Malaise</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Myalgia</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Site-stratified, 5% noninferiority test with a one-sided alpha at the 0.025 level.</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
            <estimate_desc>The upper bound of a stratified Newcombe binomial confidence interval with Cochran-Mantel-Haenszel weighting of the difference was used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Late Life Function &amp; Disability Instrument - Full Population</title>
        <description>Change in scores on the Late Life Function &amp; Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes.&#xD;
The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1).&#xD;
The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1).</description>
        <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
        <population>LLFDI data collected for only one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Late Life Function &amp; Disability Instrument - Full Population</title>
          <description>Change in scores on the Late Life Function &amp; Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes.&#xD;
The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1).&#xD;
The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1).</description>
          <population>LLFDI data collected for only one year.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Activity Limitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" lower_limit="-2.20" upper_limit="-0.66"/>
                    <measurement group_id="O2" value="-2.25" lower_limit="-2.99" upper_limit="-1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" lower_limit="-2.04" upper_limit="-0.48"/>
                    <measurement group_id="O2" value="-2.06" lower_limit="-2.77" upper_limit="-1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basic Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" lower_limit="-2.06" upper_limit="-0.68"/>
                    <measurement group_id="O2" value="-2.43" lower_limit="-3.14" upper_limit="-1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participation Restriction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" lower_limit="-1.57" upper_limit="-0.15"/>
                    <measurement group_id="O2" value="-1.58" lower_limit="-2.31" upper_limit="-0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Roles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" lower_limit="-1.55" upper_limit="0.01"/>
                    <measurement group_id="O2" value="-1.80" lower_limit="-2.58" upper_limit="-1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Instrumental Roles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" lower_limit="-1.82" upper_limit="-0.34"/>
                    <measurement group_id="O2" value="-1.66" lower_limit="-2.41" upper_limit="-0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity Limitation Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.01 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.5862</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Daily Activities Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.01 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.5648</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Basic Mobility Changes from Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.01 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.4196</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Participation Restriction Changes from Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.01 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.2418</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Social Roles Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.01 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.0746</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Instrumental Roles Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.01 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.5497</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Late Life Function &amp; Disability Instrument - Ages 65 - 79</title>
        <description>Change in scores on the Late Life Function &amp; Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes.&#xD;
The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1).&#xD;
The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1).</description>
        <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
        <population>Participants 65-79 years of age. LLFDI data collected for only one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Late Life Function &amp; Disability Instrument - Ages 65 - 79</title>
          <description>Change in scores on the Late Life Function &amp; Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes.&#xD;
The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1).&#xD;
The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1).</description>
          <population>Participants 65-79 years of age. LLFDI data collected for only one year.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Activity Limitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" lower_limit="-2.20" upper_limit="-0.50"/>
                    <measurement group_id="O2" value="-2.12" lower_limit="-2.91" upper_limit="-1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" lower_limit="-2.02" upper_limit="-0.30"/>
                    <measurement group_id="O2" value="-1.88" lower_limit="-2.60" upper_limit="-1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basic Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" lower_limit="-2.09" upper_limit="-.056"/>
                    <measurement group_id="O2" value="-2.29" lower_limit="-3.03" upper_limit="-1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participation Restriction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" lower_limit="-1.52" upper_limit="-0.10"/>
                    <measurement group_id="O2" value="-1.69" lower_limit="-2.44" upper_limit="-0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Roles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" lower_limit="-1.46" upper_limit="0.14"/>
                    <measurement group_id="O2" value="-1.98" lower_limit="-2.82" upper_limit="-1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Instrumental Roles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-1.74" upper_limit="-0.27"/>
                    <measurement group_id="O2" value="-1.70" lower_limit="-2.47" upper_limit="-0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity Limitation Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.6278</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Daily Activities Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.5622</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Basic Mobility Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.5538</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Participation Restriction Changes from Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.2310</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Social Roles Changes from Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.0435</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Instrumental Roles Changes from Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.6519</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - Late Life Function &amp; Disability Instrument - Ages 80 +</title>
        <description>Change in scores on the Late Life Function &amp; Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes.&#xD;
The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1).&#xD;
The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1).</description>
        <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
        <population>Participants 80+ years of age. LLFDI data collected for only one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - Late Life Function &amp; Disability Instrument - Ages 80 +</title>
          <description>Change in scores on the Late Life Function &amp; Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes.&#xD;
The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1).&#xD;
The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1).</description>
          <population>Participants 80+ years of age. LLFDI data collected for only one year.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Activity Limitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" lower_limit="-3.81" upper_limit="-0.08"/>
                    <measurement group_id="O2" value="-2.99" lower_limit="-5.25" upper_limit="-0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" lower_limit="-3.74" upper_limit="0.03"/>
                    <measurement group_id="O2" value="-3.13" lower_limit="-5.65" upper_limit="-0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basic Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" lower_limit="-3.22" upper_limit="-0.02"/>
                    <measurement group_id="O2" value="-3.23" lower_limit="-5.58" upper_limit="-0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participation Restriction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" lower_limit="-4.00" upper_limit="1.67"/>
                    <measurement group_id="O2" value="-0.97" lower_limit="-3.54" upper_limit="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Roles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" lower_limit="-4.31" upper_limit="1.41"/>
                    <measurement group_id="O2" value="-0.72" lower_limit="-2.98" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Instrumental Roles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" lower_limit="-4.49" upper_limit="1.42"/>
                    <measurement group_id="O2" value="-1.44" lower_limit="-4.10" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Activity Limitation Changes from Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.7483</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Daily Activities Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.7483</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Basic Mobility Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.4953</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Participation Restriction Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.8669</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Social Roles Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.8451</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Instrumental Roles Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.7376</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - EQ-5D-5L -Full Population</title>
        <description>Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups (Year 1 only).&#xD;
Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health).</description>
        <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
        <population>EQ-5D-5L data collected for only one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - EQ-5D-5L -Full Population</title>
          <description>Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups (Year 1 only).&#xD;
Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health).</description>
          <population>EQ-5D-5L data collected for only one year.</population>
          <units>Change in score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.054" lower_limit="-0.064" upper_limit="-0.044"/>
                    <measurement group_id="O2" value="-0.053" lower_limit="-0.063" upper_limit="-0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>US Index Score Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.01 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.7407</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - EQ-5D-5L - Ages 65 - 79</title>
        <description>Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only).&#xD;
Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health).</description>
        <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
        <population>Participants 65-79 years of age. EQ-5D-5L data collected for only one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - EQ-5D-5L - Ages 65 - 79</title>
          <description>Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only).&#xD;
Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health).</description>
          <population>Participants 65-79 years of age. EQ-5D-5L data collected for only one year.</population>
          <units>Change in score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.054" lower_limit="-0.065" upper_limit="-0.042"/>
                    <measurement group_id="O2" value="-0.051" lower_limit="-0.062" upper_limit="-0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>US Index Score Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.4032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - EQ-5D-5L - Ages 80 +</title>
        <description>Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only)&#xD;
Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health).</description>
        <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
        <population>Participants 80+ years of age. EQ-5D-5L data collected for only one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - EQ-5D-5L - Ages 80 +</title>
          <description>Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only)&#xD;
Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health).</description>
          <population>Participants 80+ years of age. EQ-5D-5L data collected for only one year.</population>
          <units>Change in score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.055" lower_limit="-0.074" upper_limit="-0.035"/>
                    <measurement group_id="O2" value="-0.062" lower_limit="-0.083" upper_limit="-0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>US Index Score Changes from Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.4079</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - EQ VAS -Full Population</title>
        <description>Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups (Year 1 only).&#xD;
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0).</description>
        <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
        <population>EQ VAS data collected for only one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - EQ VAS -Full Population</title>
          <description>Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups (Year 1 only).&#xD;
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0).</description>
          <population>EQ VAS data collected for only one year.</population>
          <units>Change in score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.222" lower_limit="-3.379" upper_limit="-1.065"/>
                    <measurement group_id="O2" value="-2.496" lower_limit="-3.452" upper_limit="-1.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>EQ VAS Changes for Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.01 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.7948</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - EQ VAS - Ages 65 - 79</title>
        <description>Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only).&#xD;
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0).</description>
        <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
        <population>Participants 65-79 years of age.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - EQ VAS - Ages 65 - 79</title>
          <description>Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only).&#xD;
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0).</description>
          <population>Participants 65-79 years of age.</population>
          <units>Change in score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.474" lower_limit="-3.876" upper_limit="-1.071"/>
                    <measurement group_id="O2" value="-2.791" lower_limit="-3.923" upper_limit="-1.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>EQ VAS Changes from Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. Alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.7953</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life - EQ VAS - Ages 80 +</title>
        <description>Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only).&#xD;
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0).</description>
        <time_frame>Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)</time_frame>
        <population>Participants 80+ years of age.</population>
        <group_list>
          <group group_id="O1">
            <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life - EQ VAS - Ages 80 +</title>
          <description>Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only).&#xD;
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0).</description>
          <population>Participants 80+ years of age.</population>
          <units>Change in score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.295" lower_limit="-2.966" upper_limit="0.377"/>
                    <measurement group_id="O2" value="-1.463" lower_limit="-3.163" upper_limit="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>EQ VAS Changes from Day 1 to Day 3 Group Comparisons</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-parametric testing was used to evaluate the changes from baseline to compare between groups. A two-sided alpha level set at 0.05 with no adjustments set for multiple comparisons.</non_inferiority_desc>
            <p_value>0.9329</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion - 65 and Older</title>
        <description>The proportion of subjects achieving seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer</description>
        <time_frame>Day 29 (28 days post-vaccination)</time_frame>
        <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion - 65 and Older</title>
          <description>The proportion of subjects achieving seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer</description>
          <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="23.4" upper_limit="33.2"/>
                    <measurement group_id="O2" value="26.6" lower_limit="22.0" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="14.7" upper_limit="23.3"/>
                    <measurement group_id="O2" value="23.4" lower_limit="19.0" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection - 65 and Older</title>
        <description>Proportion of subjects with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine</description>
        <time_frame>Day 29 (28 days post-vaccination)</time_frame>
        <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection - 65 and Older</title>
          <description>Proportion of subjects with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine</description>
          <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="64.4" upper_limit="74.4"/>
                    <measurement group_id="O2" value="66.9" lower_limit="61.6" upper_limit="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="79.0" upper_limit="87.1"/>
                    <measurement group_id="O2" value="83.4" lower_limit="79.0" upper_limit="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="61.4" upper_limit="71.6"/>
                    <measurement group_id="O2" value="65.7" lower_limit="60.4" upper_limit="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="86.1" upper_limit="92.7"/>
                    <measurement group_id="O2" value="88.5" lower_limit="84.6" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" lower_limit="20.1" upper_limit="29.5"/>
                    <measurement group_id="O2" value="26.9" lower_limit="22.3" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" lower_limit="38.8" upper_limit="49.6"/>
                    <measurement group_id="O2" value="48.8" lower_limit="43.4" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean HAI Titer - 65 and Older</title>
        <description>The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine</description>
        <time_frame>Day 29 (28 days post-vaccination)</time_frame>
        <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean HAI Titer - 65 and Older</title>
          <description>The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine</description>
          <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
          <units>GMT</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="44.5" upper_limit="60.3"/>
                    <measurement group_id="O2" value="50.8" lower_limit="43.4" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.6" upper_limit="115.6"/>
                    <measurement group_id="O2" value="98.0" lower_limit="84.6" upper_limit="113.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" lower_limit="52.8" upper_limit="76.1"/>
                    <measurement group_id="O2" value="58.5" lower_limit="48.4" upper_limit="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.7" lower_limit="123.2" upper_limit="162.9"/>
                    <measurement group_id="O2" value="177.3" lower_limit="152.7" upper_limit="205.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="11.9" upper_limit="15.0"/>
                    <measurement group_id="O2" value="14.7" lower_limit="12.9" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="18.5" upper_limit="25.2"/>
                    <measurement group_id="O2" value="27.5" lower_limit="23.5" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion - Ages 65-79</title>
        <description>The proportion of subjects aged 65-79 achieving seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer</description>
        <time_frame>Day 29 (28 days post-vaccination)</time_frame>
        <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion - Ages 65-79</title>
          <description>The proportion of subjects aged 65-79 achieving seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer</description>
          <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" lower_limit="24.3" upper_limit="35.6"/>
                    <measurement group_id="O2" value="27.2" lower_limit="21.9" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" lower_limit="28.5" upper_limit="40.2"/>
                    <measurement group_id="O2" value="39.5" lower_limit="33.5" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="14.5" upper_limit="24.2"/>
                    <measurement group_id="O2" value="26.1" lower_limit="20.8" upper_limit="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion - Ages 80 and Older</title>
        <description>The proportion of subjects ages 80 and older achieving seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer</description>
        <time_frame>Day 29 (28 days post-vaccination)</time_frame>
        <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion - Ages 80 and Older</title>
          <description>The proportion of subjects ages 80 and older achieving seroconversion at day 29 (an HAI titer &gt; 1:40 at day 29 if the baseline titer is &lt; 1:10 or a four-fold rise in HAI titer if the baseline titer</description>
          <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="13.1" upper_limit="33.1"/>
                    <measurement group_id="O2" value="24.7" lower_limit="15.6" upper_limit="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="17.6" upper_limit="39.1"/>
                    <measurement group_id="O2" value="35.1" lower_limit="24.5" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="9.8" upper_limit="28.5"/>
                    <measurement group_id="O2" value="14.3" lower_limit="7.4" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection - Ages 65-79</title>
        <description>Proportion of subjects ages 65-79 with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine</description>
        <time_frame>Day 29 (28 days post-vaccination)</time_frame>
        <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection - Ages 65-79</title>
          <description>Proportion of subjects ages 65-79 with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine</description>
          <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" lower_limit="64.0" upper_limit="75.3"/>
                    <measurement group_id="O2" value="65.5" lower_limit="59.4" upper_limit="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="78.7" upper_limit="87.8"/>
                    <measurement group_id="O2" value="82.8" lower_limit="77.6" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" lower_limit="61.3" upper_limit="72.8"/>
                    <measurement group_id="O2" value="65.5" lower_limit="59.4" upper_limit="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="87.4" upper_limit="94.4"/>
                    <measurement group_id="O2" value="88.1" lower_limit="83.6" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" lower_limit="17.5" upper_limit="27.8"/>
                    <measurement group_id="O2" value="19.9" lower_limit="15.3" upper_limit="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" lower_limit="36.4" upper_limit="48.5"/>
                    <measurement group_id="O2" value="45.2" lower_limit="39.1" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection - Ages 80 and Older</title>
        <description>Proportion of subjects ages 80 and older with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine</description>
        <time_frame>Day 29 (28 days post-vaccination)</time_frame>
        <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection - Ages 80 and Older</title>
          <description>Proportion of subjects ages 80 and older with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine</description>
          <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" lower_limit="56.6" upper_limit="78.7"/>
                    <measurement group_id="O2" value="71.4" lower_limit="60.0" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" lower_limit="71.5" upper_limit="89.9"/>
                    <measurement group_id="O2" value="85.7" lower_limit="75.9" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" lower_limit="52.3" upper_limit="75.1"/>
                    <measurement group_id="O2" value="66.2" lower_limit="54.6" upper_limit="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="73.0" upper_limit="91.0"/>
                    <measurement group_id="O2" value="89.6" lower_limit="80.6" upper_limit="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" lower_limit="22.3" upper_limit="44.8"/>
                    <measurement group_id="O2" value="50.6" lower_limit="39.0" upper_limit="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" lower_limit="38.7" upper_limit="62.5"/>
                    <measurement group_id="O2" value="61.0" lower_limit="49.2" upper_limit="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean HAI Titer - Ages 65-79</title>
        <description>The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine for ages 65-79</description>
        <time_frame>Day 29 (28 days post-vaccination)</time_frame>
        <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean HAI Titer - Ages 65-79</title>
          <description>The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine for ages 65-79</description>
          <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
          <units>GMT</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" lower_limit="44.3" upper_limit="62.2"/>
                    <measurement group_id="O2" value="49.5" lower_limit="41.4" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.8" lower_limit="92.1" upper_limit="128.5"/>
                    <measurement group_id="O2" value="100.9" lower_limit="84.9" upper_limit="119.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" lower_limit="51.7" upper_limit="77.5"/>
                    <measurement group_id="O2" value="56.4" lower_limit="45.5" upper_limit="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.3" lower_limit="124.3" upper_limit="169.7"/>
                    <measurement group_id="O2" value="184.4" lower_limit="155.2" upper_limit="219.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="10.8" upper_limit="13.8"/>
                    <measurement group_id="O2" value="11.8" lower_limit="10.3" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="17.2" upper_limit="24.1"/>
                    <measurement group_id="O2" value="23.8" lower_limit="20.0" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean HAI Titer - Ages 80 and Older</title>
        <description>The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine for ages 80 and older</description>
        <time_frame>Day 29 (28 days post-vaccination)</time_frame>
        <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine, Adjuvanted (FLUAD®)</title>
            <description>In the study arm, subjects will receive a single dose of FLUAD adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Influenza Vaccine (Fluzone HD)</title>
            <description>In the study arm, subjects will receive a single dose of Fluzone High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean HAI Titer - Ages 80 and Older</title>
          <description>The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine for ages 80 and older</description>
          <population>Immunogenicity Population - subjects receiving the study intervention. Participants analyzed include those that provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.</population>
          <units>GMT</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" lower_limit="35.1" upper_limit="69.3"/>
                    <measurement group_id="O2" value="55.6" lower_limit="39.2" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" lower_limit="55.2" upper_limit="97.7"/>
                    <measurement group_id="O2" value="88.7" lower_limit="66.7" upper_limit="118.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.7" lower_limit="41.4" upper_limit="98.0"/>
                    <measurement group_id="O2" value="66.5" lower_limit="43.9" upper_limit="101.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.2" lower_limit="93.4" upper_limit="178.8"/>
                    <measurement group_id="O2" value="155.0" lower_limit="114.2" upper_limit="210.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="14.6" upper_limit="24.0"/>
                    <measurement group_id="O2" value="31.2" lower_limit="23.2" upper_limit="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B - Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="19.0" upper_limit="38.2"/>
                    <measurement group_id="O2" value="45.0" lower_limit="31.8" upper_limit="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events, Serious Adverse Events, and All-Cause Mortality rates were collected 42 days post vaccination. Serious Adverse Events and Mortality Rates were collected up to 181 days for the longer-term immunogenicity subset</time_frame>
      <desc>The two reported deaths occurred &gt;42 days post vaccination</desc>
      <group_list>
        <group group_id="E1">
          <title>Adjuvanted Influenza Vaccine (FLUAD®)</title>
          <description>In the study arm, subjects will receive a single dose of FLUAD® adjuvanted influenza vaccine during Visit 1.&#xD;
FLUAD®: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
        </group>
        <group group_id="E2">
          <title>High-dose Influenza Vaccine (Fluzone® HD)</title>
          <description>In the study arm, subjects will receive a single dose of Fluzone® High-Dose influenza vaccine during Visit 1.&#xD;
Fluzone® High-Dose: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Metastatic squamous cell</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Stressed induced cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Post-operative ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>TIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Near syncope due to orthostatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
              <event>
                <sub_title>Pulmonary emboli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="378"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="378"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <description>Cold symptoms</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="378"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="379"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kenneth Schmader</name_or_title>
      <organization>Duke University</organization>
      <phone>919-660-7572</phone>
      <email>kenneth.schmader@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

